December 12, 2008
Gilead Sciences Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 12, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has filed a
lawsuit in U.S. District Court in New York against Teva Pharmaceuticals
USA, Inc. and Teva Pharmaceutical Industries, Ltd. for infringement of
U.S. Patent Numbers 6,642,245 and 6,703,396. Both patents are associated
with emtricitabine, a component of Truvada(R) (emtricitabine
and tenofovir disoproxil fumarate), and are licensed exclusively to
Gilead Sciences by Emory University. Truvada is indicated in combination
with other antiretroviral agents for the treatment of HIV-1 infection in
The lawsuit is based on an Abbreviated New Drug Application filed by
Teva Pharmaceuticals USA, Inc., which seeks approval to manufacture and
market a generic version of Truvada before the expiration of both
Gilead has full confidence in the strength of its patent position and
plans to vigorously defend the intellectual property rights of Truvada.
Truvada is currently protected by 10 patents, which are listed in the
FDA's Approved Drugs Products List, and all 10 patents would need to be
invalidated or expired before a generic version of Truvada could be
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company's mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Australia.
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors, including
uncertainty related to whether the infringement lawsuit against Teva
Pharmaceuticals USA, Inc. will be successful. These risks, uncertainties
and other factors could cause actual results to differ materially from
those referred to in the forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. These and
other risks are described in detail in Gilead's Annual Report on Form
10-K for the year ended December 31, 2007 and its Quarterly Report on
Form 10-Q for the first, second and third quarters of 2008, as filed
with the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
Truvada is a registered trademark of Gilead Sciences, Inc.
For more information on Gilead, please call the Gilead Public Affairs
Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.
CONTACT: Gilead Sciences, Inc.
Susan Hubbard, Investors, 650-522-5715
Cara Miller, Media, 650-522-1616
Source: Gilead Sciences, Inc.